New combo therapy aims to prevent dangerous pregnancy condition
NCT ID NCT07361679
First seen Jan 30, 2026 · Last updated Jun 16, 2026 · Updated 16 times
Summary
This study tests whether adding a blood thinner (low molecular weight heparin) to daily low-dose aspirin can prevent preeclampsia in pregnant women at high risk. Preeclampsia is a serious condition causing high blood pressure and organ damage. The trial will enroll 100 women early in pregnancy and compare the two treatments to see which works better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREECLAMPSIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Department of Obstetrics and Gynecology, Alexandra Hospital
RECRUITINGAthens, Attica, 11528, Greece
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.